A prospective randamized admininstration of Stronger-Neo-Minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon.

The Use of Selected Nutrition Supplements and Complementary and Alternative Medicine in Liver Disease

“…A smaller study compared INF-α (6 MU per day for 8 weeks) vs INF-α plus SNMC for 8 weeks. 168 Again, no significant changes in serum biomarkers and virological response were seen at 8 weeks and at 6 months of follow-up. Thus, very limited studies have not shown enhanced antiviral effects with glycyrrhizin.…”

Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review

“…Two publications provide a thorough analysis of the adverse events experienced during the trial [40, p. 1165]; there were no significant differences between groups in the number of patients reporting an adverse event, although in the study by van Rossum et al significantly more patients reported cold/flu symptoms in the 160 mg group compared with placebo. Suzuki et al reported one adverse event (bleeding in the fundus) which occurred during combination treatment with glycyrrhizin and interferon-a [39]. In the final study, no patients complained of drug related symptoms or developed signs of an adverse reaction during the treatment period [41].…”

“…In two trials, patients received SNMC in combination with interferon-a [38,39]; there were no significant differences In terms of biochemical response C was significantly ðP , 0:05Þ more effective than A at follow-up; no other significant differences between treatments at any time-point. In terms of virological response C was significantly ðP , 0:05Þ more effective than B at follow-up; no other significant differences between treatments at any time-point between treatments in the number of patients achieving biochemical or virological response in either study.…”

Viusid, a nutritional supplement, in combination with interferon α‐2b and ribavirin in patients with chronic hepatitis C

“…The administration of antioxidant and immunomodulatory drugs for different disorders, including CHC, has generated a lot of interest recently; however, heterogeneous or controversial results on virologic, biochemical and histologic responses were observed between treatment regimens in any of the trials (12–17).…”